Anemia in Chronic Kidney Disease (Renal Anemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Renal anemia is a disease in which the patient has an unusually low count of red blood cells. Renal is a term that means the kidneys, so anemia is often associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, become short of breath, dizziness, and inability to think clearly.

The renal anemia pipeline market research report provides comprehensive information on the therapeutics under development for renal anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for renal anemia and features dormant and discontinued projects.

Renal Anemia Pipeline Products Market Segmentation by Targets

The key targets in the renal anemia pipeline products market are Erythropoietin Receptor, Transmembrane Prolyl 4 Hydroxylase, Egl Nine Homolog 1, Egl Nine Homolog 3, Prolyl Hydroxylase EGLN2, and Phosphate. Erythropoietin Receptor is the leading target in the pipeline.

Renal Anemia Pipeline Products Market Analysis by Targets

For more target insights into the renal anemia pipeline products market, download a free report sample

Renal Anemia Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the renal anemia pipeline products market are Erythropoietin Receptor Agonist, Transmembrane Prolyl 4 Hydroxylase Inhibitor, Egl Nine Homolog 1 Inhibitor, Egl Nine Homolog 3 Inhibitor, Prolyl Hydroxylase EGLN2 Inhibitor, and Phosphate Binder. Erythropoietin Receptor Agonist is the leading MoA in the pipeline market.

Renal Anemia Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the renal anemia pipeline products market, download a free report sample

Renal Anemia Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the renal anemia pipeline products market are oral, subcutaneous, intravenous, topical, and transdermal. Oral is the leading RoA.

Renal Anemia Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the renal anemia pipeline products market, download a free report sample

Renal Anemia Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the renal anemia pipeline products market are recombinant protein, small molecule, fusion protein, protein, and synthetic peptide. Recombinant protein is the leading molecule type.

Renal Anemia Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the renal anemia pipeline products market, download a free report sample

Renal Anemia Pipeline Products Market - Competitive Landscape

Some of the leading companies in the renal anemia pipeline products market are 3SBio Inc, Japan Tobacco Inc, Akebia Therapeutics Inc, GSK plc, UBI Pharma Inc, Xenetic Biosciences Inc, Zydus Lifesciences Ltd, and Avesthagen Ltd among others. 3SBio Inc is the leading company in the renal anemia pipeline products market.

Renal Anemia Pipeline Products Market Analysis by Companies

To know more about the leading players in the renal anemia pipeline products market, download a free report sample

Renal Anemia Pipeline Products Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of renal anemia.
• The pipeline guide reviews pipeline therapeutics for renal anemia by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in renal anemia therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates renal anemia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for renal anemia

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for renal anemia.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the renal anemia pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.